Multifunctional Nanoparticles for Photothermally Controlled Drug Delivery and Magnetic Resonance Imaging Enhancement

Department of Physics, Yonsei University, Seoul 120-742, Korea.
Small (Impact Factor: 8.37). 02/2008; 4(2):192-6. DOI: 10.1002/smll.200700807
Source: PubMed


The use of biodegradable polymer-metal multilayer half-shell nanoparticles (H-S NPs) for photothermally controlled drug delivery and magnetic resonance imaging enhancement, was analyzed. The drug is encapsulated within biocompatible and biodegradable polymer nanoparticles, where metal multilayers are deposited on these nanoparticles. The absorption spectra was measured of the nanoparticle using a UV-visible/NIR spectrometer for poly(lactic-co-glycolic acid) (PLGA)-Au H-S NPs. The optical and photothermal conversion properties of rhodamine-loaded PLGA-Au H-S NPs with PLGA nanoparticles were examined. Rhodamine release was monitored from PLGA nanoparticles using total internal reflection fluorescence microscopy (TIRFM). Results show that these nanoparticles can efficiently achieve their selective cell target.

Download full-text


Available from: Jaemoon Yang, Apr 25, 2014
  • Source
    • "Near-infrared (NIR) resonant nanomaterials such as Au nanorods (GNRs) [7,12,13], multi-branched particles [14,15], nanoshells [16], and hollow-shells (HSs) [11,17] are attractive therapeutic agents because they can deliver drugs via non-invasive hyperthermia . NIR light in the range of 700e900 nm has been widely used to locally raise cell temperature, thereby optimizing the photothermal effect [18]. Triggered drug release by an external stimulus such as NIR irradiation could significantly advance cancer treatment by overcoming the indiscriminate drug distribution observed in conventional drug delivery. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Au/Ag hollow nanoshells (AuHNSs) were developed as multifunctional therapeutic agents for effective, targeted, photothermally induced drug delivery under near-infrared (NIR) light. AuHNSs were synthesized by galvanic replacement reaction. We further conjugated antibodies against the epidermal growth factor receptor (EGFR) to the PEGylated AuHNS, followed by loading with the antitumor drug doxorubicin (AuHNS-EGFR-DOX) for lung cancer treatment. AuHNSs showed similar photothermal efficiency to gold nanorods under optimized NIR laser power. The targeting of AuHNS-EGFR-DOX was confirmed by light-scattering images of A549 cells, and doxorubicin release from the AuHNSs was evaluated under low pH and NIR-irradiated conditions. Multifunctional AuHNS-EGFR-DOX induced photothermal ablation of the targeted lung cancer cells and rapid doxorubicin release following irradiation with NIR laser. Furthermore, we evaluated the effectiveness of AuHNS-EGFR-DOX drug delivery by comparing two drug delivery methods: receptor-mediated endocytosis and cell-surface targeting. Accumulation of the AuHNS-EGFR-DOX on the cell surfaces by targeting EGFR turned out to be more effective for lung cancer treatments than uptake of AuHNS-EGFR-DOX. Taken together, our data suggest a new and optimal method of NIR-induced drug release via the accumulation of targeted AuHNS-EGFR-DOX on cancer cell membranes.
    Biomaterials 03/2015; 45:81–92. DOI:10.1016/j.biomaterials.2014.12.036 · 8.56 Impact Factor
  • Source
    • "They are expected to increase the efficacy of therapeutic agents, while reducing unwanted side effects, such as toxicity. In addition, they could greatly curb the systemic side effect of anticancer drugs by regulating drug release kinetics [11,14,129,130,131,132,133]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nanoparticles have been investigated as drug carriers, because they provide a great opportunity due to their advantageous features: (i) various formulations using organic/inorganic materials, (ii) easy modification of targeting molecules, drugs or other molecules on them, (iii) effective delivery to target sites, resulting in high therapeutic efficacy and (iv) controlling drug release by external/internal stimuli. Because of these features, therapeutic efficacy can be improved and unwanted side effects can be reduced. Theranostic nanoparticles have been developed by incorporating imaging agents in drug carriers as all-in-one system, which makes it possible to diagnose and treat cancer by monitoring drug delivery behavior simultaneously. Recently, stimuli-responsive, activatable nanomaterials are being applied that are capable of producing chemical or physical changes by external stimuli. By using these nanoparticles, multiple tasks can be carried out simultaneously, e.g., early and accurate diagnosis, efficient cataloguing of patient groups of personalized therapy and real-time monitoring of disease progress. In this paper, we describe various types of nanoparticles for drug delivery systems, as well as theranostic systems.
    Pharmaceutics 06/2013; 5(2):294-317. DOI:10.3390/pharmaceutics5020294
  • Source
    • "Several non-viral polymers [9-11], cationic lipids [12-14], and peptides [15-17] have been used to form nanosized polyelectrolyte complexes via electrostatic interactions with siRNA. In addition, gold nanoparticles (AuNPs) have also been used for intracellular drug delivery [18-22]. AuNPs have also been used for nucleic acid delivery [23-30]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Several nanoconjugates have been designed to deliver nucleic acids such as small interfering RNA (siRNA) and DNA to cells to study silencing and expression efficacies. In the present study, we prepared novel epithelial cell adhesion molecule (EpCAM) monoclonal antibody conjugated polyethyleneimine (PEI) capped gold nanoparticles (AuNPs) loaded with EpCAM-specific siRNA molecules to knock-down the EpCAM gene in retinoblastoma (RB) cells. We chose EpCAM as a target moiety to deliver siRNA because this molecule is highly expressed in various epithelial cancers and is an ideal target as it is highly expressed in the apical surface of tumor cells while showing basolateral expression in normal cells. The EpCAM antibody was conjugated to AuNP-PEI loaded with siRNA molecules to specifically deliver siRNA to EpCAM-expressing RB cells. Conjugation efficiencies were confirmed with ultraviolet-visible spectrophotometry, Fourier transform infrared spectroscopy, and agarose and SDS-polyacrylamide gel electrophoresis. The size and zeta potential were measured using a Zeta sizer analyzer. Nanoparticle internalization and uptake were studied using fluorescent microscopy and flow cytometry. Gene silencing efficacy was monitored with western blot analysis and real-time quantitative PCR. Optimal size and neutral zeta potential properties of the AuNP-PEI- EpCAM antibody (EpAb) antibody were achieved for the transfection studies. The AuNP-PEI nanoparticles did not show any cytotoxicity to the cells, which means these nanomaterials are suitable for intracellular delivery of siRNA for therapeutic interventions. With EpCAM antibody conjugation, PEI-capped AuNPs loaded with EpCAM siRNA were significantly internalized in the Y79 cells as observed with fluorescence microscopy and flow cytometry and induced a highly significant reduction in the cell viability of the Y79 cells. Through increased binding of EpCAM antibody-conjugated AuNP-PEI nanoparticles, significant downregulation of EpCAM gene was observed in the Y79 cells when compared to the cells treated with the antibody-unconjugated AuNP-PEI nanoparticles. Thus, a novel antibody conjugated nanocarrier designed to deliver siRNA holds promise as an effective gene therapy strategy for retinoblastoma in the near future. In addition to serving as an siRNA delivery tool for therapy, gold nanoparticles can also serve as imaging modality in diagnosis.
    Molecular vision 05/2013; 19:1029-1038. · 1.99 Impact Factor
Show more